Quoin Pharmaceuticals (QNRX) Proxy filing summary

Executive summary

• Special meeting set for Nov. 12, 2026; record date Sept. 23, 2026. Board recommends FOR both proposals.

• Main item would let private-placement warrant holders raise beneficial ownership and voting limits from 4.99% to no more than 9.99%, subject to written notice.

Voting matters and shareholder proposals

• Proposal 1 covers warrants issued in the Oct. 2025 and Aug. 2026 private placements; any limit increase takes effect on the 61st day after notice.

• Proposal 2 would permit adjournment to seek additional votes if needed; approval of each proposal requires a majority of votes cast, with abstentions excluded.

• Quorum requires at least two shareholders representing 33.5% of voting power; a reconvened meeting may proceed with any shareholders present if quorum is again absent.

Board of directors and corporate governance

• The Board recommends FOR Proposals 1 and 2; Dr. Michael Myers serves as Board chair and CEO.

• Dennis Langer, Michael Myers, Denise Carter, Sally Lawlor and James Culverwell participated in one or both private placements.